<DOC>
	<DOCNO>NCT02076971</DOCNO>
	<brief_summary>The purpose study determine sensitivity specificity QuantiFeron® ImmuKnow® combination early detection patient develop CMV infection lung transplant patient CMV-positive serology ( R+ ) prior transplant .</brief_summary>
	<brief_title>Cytomegalovirus-Specific Response Measured QuantiFeron® Overall Immunologic Response Measured ImmuKnow® Lung Transplant Patients CMV-positive</brief_title>
	<detailed_description>The secondary objective study : - To evaluate Cytomegalovirus ( CMV ) -specific immune response measure QuantiFeron® . - To evaluate overall immune response measure ImmuKnow® . - To study course QuantiFeron® ImmuKnow®over follow-up period . - To correlate level ImmuKnow® QuantiFeron® . - To evaluate relationship level dose immunosuppressant relationship degree overall immunosuppression ( ImmuKnow® ) . - To evaluate relationship infection , immunological complication degree overall immunosuppression ( ImmuKnow® ) .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<criteria>Patients age ≥ 18 year . Men woman receive lung transplant . CMVseropositive patient ( R+ ) . Patients inform study procedure sign informed consent form . Over 3 month posttransplant . Patients expect able follow first 12 month posttransplant . Patient participation another clinical trial study criterion exclusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Lung transplant</keyword>
	<keyword>Quantiferon</keyword>
	<keyword>Immuknow</keyword>
</DOC>